Lars Poulsen Tolbod

Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients : A double-blind, randomized, placebo-controlled LIVE sub-study. / Nielsen, Roni; Jorsal, Anders; Iversen, Peter; Tolbod, Lars Poulsen; Bouchelouche, Kirsten; Sørensen, Jens; Harms, Hendrik Johannes; Flyvbjerg, Allan; Tarnow, Lise; Kistorp, Caroline; Gustafsson, Ida; Bøtker, Hans Erik; Wiggers, Henrik.

In: Journal of Nuclear Cardiology, 02.08.2017.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{1c775a8a18644be486c8c4c10eade9c6,
title = "Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study",
abstract = "BACKGROUND: The glucagon-like peptide-1 analog liraglutide increases heart rate and may be associated with more cardiac events in chronic heart failure (CHF) patients. We studied whether this could be ascribed to effects on myocardial glucose uptake (MGU), myocardial blood flow (MBF) and MBF reserve (MFR).METHODS AND RESULTS: CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design. Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by (18)F-FDG and (15)O-H2O positron emission tomography. Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004). Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups. Furthermore, there was no association between the level of insulin resistance at baseline and changes in MGU in patients treated with liraglutide.CONCLUSION: Liraglutide did not affect MGU, MBF, or MFR in non-diabetic CHF patients. Any potential increase in cardiac events in these patients seems not to involve changes in MGU, MBF, or MFR.TRIAL REGISTRATION: Trial registry: http://www.ClinicalTrials.org . Identifier: NCT01472640. Url: https://clinicaltrials.gov/ct2/show/NCT01472640?term=NCT01472640&rank=1.",
keywords = "Journal Article",
author = "Roni Nielsen and Anders Jorsal and Peter Iversen and Tolbod, {Lars Poulsen} and Kirsten Bouchelouche and Jens S{\o}rensen and Harms, {Hendrik Johannes} and Allan Flyvbjerg and Lise Tarnow and Caroline Kistorp and Ida Gustafsson and B{\o}tker, {Hans Erik} and Henrik Wiggers",
year = "2017",
month = aug,
day = "2",
doi = "10.1007/s12350-017-1000-2",
language = "English",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer New York LLC",

}

RIS

TY - JOUR

T1 - Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients

T2 - A double-blind, randomized, placebo-controlled LIVE sub-study

AU - Nielsen, Roni

AU - Jorsal, Anders

AU - Iversen, Peter

AU - Tolbod, Lars Poulsen

AU - Bouchelouche, Kirsten

AU - Sørensen, Jens

AU - Harms, Hendrik Johannes

AU - Flyvbjerg, Allan

AU - Tarnow, Lise

AU - Kistorp, Caroline

AU - Gustafsson, Ida

AU - Bøtker, Hans Erik

AU - Wiggers, Henrik

PY - 2017/8/2

Y1 - 2017/8/2

N2 - BACKGROUND: The glucagon-like peptide-1 analog liraglutide increases heart rate and may be associated with more cardiac events in chronic heart failure (CHF) patients. We studied whether this could be ascribed to effects on myocardial glucose uptake (MGU), myocardial blood flow (MBF) and MBF reserve (MFR).METHODS AND RESULTS: CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design. Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by (18)F-FDG and (15)O-H2O positron emission tomography. Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004). Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups. Furthermore, there was no association between the level of insulin resistance at baseline and changes in MGU in patients treated with liraglutide.CONCLUSION: Liraglutide did not affect MGU, MBF, or MFR in non-diabetic CHF patients. Any potential increase in cardiac events in these patients seems not to involve changes in MGU, MBF, or MFR.TRIAL REGISTRATION: Trial registry: http://www.ClinicalTrials.org . Identifier: NCT01472640. Url: https://clinicaltrials.gov/ct2/show/NCT01472640?term=NCT01472640&rank=1.

AB - BACKGROUND: The glucagon-like peptide-1 analog liraglutide increases heart rate and may be associated with more cardiac events in chronic heart failure (CHF) patients. We studied whether this could be ascribed to effects on myocardial glucose uptake (MGU), myocardial blood flow (MBF) and MBF reserve (MFR).METHODS AND RESULTS: CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design. Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by (18)F-FDG and (15)O-H2O positron emission tomography. Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004). Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups. Furthermore, there was no association between the level of insulin resistance at baseline and changes in MGU in patients treated with liraglutide.CONCLUSION: Liraglutide did not affect MGU, MBF, or MFR in non-diabetic CHF patients. Any potential increase in cardiac events in these patients seems not to involve changes in MGU, MBF, or MFR.TRIAL REGISTRATION: Trial registry: http://www.ClinicalTrials.org . Identifier: NCT01472640. Url: https://clinicaltrials.gov/ct2/show/NCT01472640?term=NCT01472640&rank=1.

KW - Journal Article

U2 - 10.1007/s12350-017-1000-2

DO - 10.1007/s12350-017-1000-2

M3 - Journal article

C2 - 28770459

JO - Journal of Nuclear Cardiology

JF - Journal of Nuclear Cardiology

SN - 1071-3581

ER -